NHS to tell 1 7 million more Brits to shield in major Covid-19 change in England chroniclelive.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chroniclelive.co.uk Daily Mail and Mail on Sunday newspapers.
Date Time
New technology to help identify those at high risk from COVID-19
New predictive risk model to help clinicians identify adults with multiple risk factors that make them more vulnerable to COVID-19
Over 800,000 adults will now be prioritised to receive a vaccine as part of the current vaccination cohorts
Research is developed by subgroup of NERVTAG, led by the University of Oxford and funded by the National Institute for Health Research (NIHR)
New technology has been introduced in England to help clinicians identify, for the first time, a new group of people who may be at high risk from COVID-19. Over 800,000 adults will now be prioritised to receive a vaccine as part of the current vaccination cohorts.
A new risk-prediction model devised by Oxford University scientists is to be deployed as new technology by the National Health Service (NHS) in England to help clinicians identify a new group of people who may be at high risk from COVID-19.
800,000 people will now be prioritised for vaccines because of high risk from Covid liverpoolecho.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from liverpoolecho.co.uk Daily Mail and Mail on Sunday newspapers.
AGILE is a UK clinical trial platform for rapid clinical evaluation of potential COVID treatments.
A major clinical trial platform designed for the rapid clinical evaluation of potential COVID-19 treatments has received a multi-million pound funding boost to aid its expansion.
The AGILE testing platform, co-led by researchers at the NIHR Southampton Clinical Trials Unit at the University of Southampton, has received £3.2m from the UK government’s Department of Health and Social Care to fast track the clinical trials of innovative treatments against the coronavirus.
Awarded by the Medical Research Council and co-funded through the National Institute of Health Research (NIHR), this new money will allow AGILE’s activity to be expanded nationally into five UK centres, and complements funding from the Wellcome Trust and UNITAID in addition to funding announcements from industry.